Biogen has grown revenue −0.55% a year over three years and −4.6% a year over five, with earnings per share compounding at −24%. Revenue growth, 3-year annual rate: −0.55% (Drug Manufacturers - General median +6.3%). Revenue growth, 5-year rate: −4.6%, growth has picked up over the last three years. Earnings per share, 3-year rate: −24%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 19, FY2007 to FY2025, as filed.

BIIBBiogen

HealthcareUSD

$221.12

$127.7552 weeks$221.50

Is it growing?

Is BIIB growing?

Biogen has grown revenue −0.55% a year over three years and −4.6% a year over five, with earnings per share compounding at −24%.

−0.55%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −4.6%
Revenue growth, 5-year rate · −0.55% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: −24%
Earnings per share, 3-year rate · revenue −0.55% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 19
Years of annual history on file · FY2007 to FY2025, as filed